Of all the generic Harvoni copies Twinvir has been on the market for the longest so it should come as no surprise that the SVR12 results for it are the first to arrive.
And what do they say? Well, I just had a look and the news is good.
First let me mention that making ledipasvir bioavailable is not trivial and that Incepta use the same processes used by Gilead - in other words they have done their homework. I should also mention that like Harvoni, Twinvir is not 100% effective and patients can, will and do fail taking the new DAAs, but....
Our current results indicate Twinvir delivers the same clinical results as Harvoni so if this is your chosen medication chances are SVR will be yours.